Clinicians Map Group at High Risk for Aggressive, 'Hidden' Prostate Cancer

Key points
- Clinical researchers at Princess Margaret Hospital (PMH) can now answer the question that baffles many clinicians - why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer?
- Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer.
- The answer is hidden tumours located on the top of the prostate that evade traditional diagnostic procedures, including ultrasound-guided needle biopsy.
- "Our findings identify a specific high-risk group whose tumours are difficult to diagnose because of location.
Clinical researchers at Princess Margaret Hospital (PMH) can now answer the question that baffles many clinicians - why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer?
The answer is hidden tumours located on the top of the prostate that evade traditional diagnostic procedures, including ultrasound-guided needle biopsy. The PMH research, published online today in the British Journal of Urology International (BJU 8938), demonstrates that magnetic resonance imaging (MRI) is the best tool to reveal such tumours.
"Our findings identify a specific high-risk group whose tumours are difficult to diagnose because of location. These men benefit from MRI, which guides the biopsy procedure with a high degree of accuracy," says author Dr. Nathan Lawrentschuk, Urologic Oncology Fellow, PMH Cancer Program, University Health Network. "The research team calls the clinical presentation of elevated PSA and repeated negative biopsy results in 'prostate evasive anterior tumour syndrome' (PEATS)."
"Knowing about PEATS may also be important for men already on 'active surveillance' - patients with slow - growing prostate cancer who are being regularly monitored through PSA testing and biopsy. Every man does not need an MRI, but knowing about PEATS will help us identify those who do," says principal investigator Dr. Neil Fleshner, Head of the Division of Urology, Princess Margaret Hospital, Professor of Surgery at University of Toronto, and Love Chair in Prostate Cancer Prevention Research.
A team of urologists, surgeons, radiologists and pathologists studied 31 PMH patients who had positive biopsy results and tumours on top of their prostate as shown on MRI. They found that MRI was able to help diagnose hidden prostate tumours 87% of the time.
Dr. Lawrentschuk says clinicians need to be aware of PEATS because these hidden tumours can be aggressive.
About Princess Margaret Hospital
Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer. Princess Margaret Hospital is a member of University Health Network, which also includes Toronto General Hospital and Toronto Western Hospital. All three are research hospitals affiliated with the University of Toronto. www.uhn.ca
Source: University Health Network (UHN)
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsIVF Babies May Be at Higher Cancer Risk
Children born after in vitro fertilization (IVF) or other fertility treatments appear to be at modestly elevated risk of cancer, although causality still isn't clear, a meta-analysis showed. The risk of any childhood…
11 April 2013
NewsLow levels of serum bilirubin spell higher lung cancer risk for male smokers
Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the…
8 April 2013
NewsMoffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic…





